Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

High-dose Chemotherapy and ASCT or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma (MATRix)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02531841
Recruitment Status : Unknown
Verified August 2015 by Elisabeth Schorb, University Hospital Freiburg.
Recruitment status was:  Recruiting
First Posted : August 25, 2015
Last Update Posted : August 25, 2015
Sponsor:
Collaborators:
German Federal Ministry of Education and Research
International Extranodal Lymphoma Study Group (IELSG)
Information provided by (Responsible Party):
Elisabeth Schorb, University Hospital Freiburg

Tracking Information
First Submitted Date  ICMJE August 14, 2015
First Posted Date  ICMJE August 25, 2015
Last Update Posted Date August 25, 2015
Study Start Date  ICMJE July 2014
Estimated Primary Completion Date November 2017   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: August 24, 2015)
The primary outcome measure PFS will be measured by the number of events (PD, relapse or death from any cause) within the treatment arms [ Time Frame: PFS is defined as the time from randomization until PD or relapse or death from any cause up to 24 months after end of treatment ]
Progression-free survival PFS: Response Assessment III at the end of study treatment (EOT) visit and every imaging diagnostic assessments during follow-up period: during year 1-2: every 3 month
Original Primary Outcome Measures  ICMJE Same as current
Change History No Changes Posted
Current Secondary Outcome Measures  ICMJE
 (submitted: August 24, 2015)
  • The secondary outcome measure CR will be assessed on day 60 after randomization using the IPCG response criteria [ Time Frame: CR will be determined on day 60 after randomization ]
    Response will be measured by the IPCG response criteria.
  • The secondary outcome measure Response duration will be measured by the time from CR, CRu or PR until relapse or PD using the IPCG response criteria [ Time Frame: Time from CR, CRu or PR until relapse or PD up to 24 months after end of treatment ]
    Response duration observation times for patients where the event of interest was not observed, will be censored at the time last seen alive. Timepoints of evaluation are defined as every assessment during follow up period in accordance with the protocol. year 1-2: every 3 month
  • The secondary outcome OS is measured as time from randomization until death of any cause [ Time Frame: OS is defined as time from randomization until death of any cause up to 24 months after end of treatment ]
    Timepoints of evaluation are defined as every assessment during follow up period in accordance with the protocol. year 1-2: every 3 month
  • Number of patients with (Serious) adverse events as assessed by CTCAE v4.0 [ Time Frame: All SAEs that occur starting from the first administration of the study medication until day 60 after randomization. ]
    After this time period, only SAEs judged by the investigator to be related to at least one of investigational products will be reported
  • Number of patients with treatment related toxicity as assessed by CTCAE v4.0 [ Time Frame: All toxicities that occur starting from the first administration of the study medication until day 60 after randomization. ]
    If an abnormal parameter is not listed in the toxicity table, an AE must be documented
  • Number of patients with neurotoxicity assessed by MMSE, EORTC QLQ-BN20 and the neuro-psychological battery [ Time Frame: All parameters of neurotoxicity that occur starting from the first administration of the study medication up to 24 months after end of treatment. ]
    Timepoints of evaluation are defined as every assessment during follow up period in accordance with the protocol
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE High-dose Chemotherapy and ASCT or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma
Official Title  ICMJE High-dose Chemotherapy and Autologous Stem Cell Transplant or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma - Randomized Phase III Trial
Brief Summary In the presently planned multicentre Phase III trial the two therapies will be compared: Patients will be randomized after intensified induction treatment with 4 cycles rituximab, methotrexate, cytarabine and thiotepa (MATRix) between first-line high-dose chemotherapy against conventional consolidating therapy with 2 cycles of conventional chemotherapy with R-DeVIC (rituximab, dexamethasone, etoposide, ifosfamide, carboplatin).
Detailed Description

Trial purpose and rationale Primary central nervous system lymphoma (PCNSL) is a highly aggressive disease with rising incidence over the past 30 years. Similar to other hematological diseases, the rationale for consolidation in PCNSL is the elimination of minimal residual disease. The efficacy of WBRT, which is the current standard for consolidation after HD-MTX-based systemic treatment, is being compared to HDT-ASCT in the ongoing IELSG-32 trial.

High-dose chemotherapy with carmustine or busulfan and thiotepa followed by autologous stem cell transplantation has been shown to be feasible and highly effective in newly diagnosed eligible patients, but also in the salvage situation.

The question we aim to answer is whether HDT-ASCT is superior to conventional therapy as consolidation after intensified immunochemotherapy in newly diagnosed PCNSL.

Rationale for this study:

Based on previously obtained good results from the treatment of recurrent or refractory PCNSL the DeVIC protocol was chosen for conventional consolidation treatment. This protocol, originally designed as a salvage protocol for aggressive NHL, crosses the blood-brain barrier and consists of multidrug resistant unrelated agents.

Treatment plan and procedure

Interventions

Induction treatment 4 cycles (every 3 weeks), stem-cell harvest after 2nd cycle:

  • Rituximab 375 mg/m²/d i.v. (d 0,5)
  • Methotrexate 3,5 g/m² i.v. (d1)
  • Cytarabine 2 x 2 g/m²/d i.v. (d2-3)
  • Thiotepa 30 mg/m² i.v. (d4)

Patients with PD after two cycles, SD/PD after four cycles of induction therapy or insufficient stem-cell harvest after three cycles are ineligible for randomization.

Consolidation Arm A 2 cycles of R-DeVIC (every 3 weeks):

  • Rituximab 375 mg/m²/d i.v. (d0)
  • Dexamethasone 40 mg/d i.v. (d1-3)
  • Etoposide 100 mg/m²/d i.v. (d1-3)
  • Ifosfamide 1500 mg/m²/d i.v. (d1-3)
  • Carboplatin 300 mg/m² i.v. (d1)

Consolidation Arm B

High-dose chemotherapy (HDT-ASCT):

  • Carmustine* 400 mg/m² i.v. (d-6)
  • Thiotepa 2 x 5 mg/kg/d i.v. (d-5-(-4))
  • Autologous Stem Cell Transplantation (d0)

    * if carmustine is not available at the investigation site, busulfan can be administered instead:

  • Busulfan 3,2 mg/kg/d (d-8-(-7))
  • Thiotepa 2 x 5 mg/kg/d i.v. (d-5-(-4))
  • Autologous Stem Cell Transplantation (d0)
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Diffuse Large B-cell-lymphoma
Intervention  ICMJE
  • Drug: Arm A (Fortecortin®-ETOPOPHOS®-IFO-cell®-CARBO-cell®)

    Arm A 4 cycles MATRix (every 3 weeks), stem-cell harvest after 2nd cycle:

    • Rituximab 375 mg/m²/d i.v. (d0,5)
    • Methotrexate 3.5 g/m² i.v. (d1)
    • Cytarabine 2 x 2 g/m²/d i.v. (d2-3)
    • Thiotepa 30 mg/m² i.v. (d4) Consolidation 2 cycles of R-DeVIC (every 3 weeks):
    • Rituximab 375 mg/m²/d i.v. (d0)
    • Dexamethasone 40 mg/d i.v. (d1-3)
    • Etoposide 100 mg/m²/d i.v. (d1-3)
    • Ifosfamide 1500 mg/m²/d i.v. (d1-3)
    • Carboplatin 300 mg/m² i.v. (d1)
    Other Name: Fortecortin®-ETOPOPHOS®-IFO-cell®-CARBO-cell®
  • Drug: Arm B (TEPADINA®-CARMUBRIS®-Busilvex®)

    4 cycles MATRix (every 3 weeks), stem-cell harvest after 2nd cycle:

    • Rituximab 375 mg/m²/d i.v. (d0,5)
    • Methotrexate 3.5 g/m² i.v. (d1)
    • Cytarabine 2 x 2 g/m²/d i.v. (d2-3)
    • Thiotepa 30 mg/m² i.v. (d4) Consolidation

    High-dose chemotherapy (HDT-ASCT):

    • Carmustine* 400 mg/m² i.v. (d-6)
    • Thiotepa 2 x 5 mg/kg/d i.v. (d-5-(-4))
    • Autologous Stem Cell Transplantation (d0)

      * if carmustine is not available at the investigation site, busulfan can be administered instead:

    • Busulfan 3,2 mg/kg/d (d-8-(-7))
    • Thiotepa 2 x 5 mg/kg/d i.v. (d-5-(-4))
    • Autologous Stem Cell Transplantation (d0)
    Other Name: TEPADINA®-CARMUBRIS®-Busilvex®
Study Arms  ICMJE
  • Active Comparator: Arm A

    Induction Treatment 4 cycles MATRix (every 3 weeks), stem-cell harvest after 2nd cycle:

    • Rituximab 375 mg/m²/d i.v. (d0,5)
    • Methotrexate 3.5 g/m² i.v. (d1)
    • Cytarabine 2 x 2 g/m²/d i.v. (d2-3)
    • Thiotepa 30 mg/m² i.v. (d4)

    Consolidation Treatment 2 cycles of R-DeVIC (every 3 weeks):

    • Rituximab 375 mg/m²/d i.v. (d0)
    • Dexamethasone 40 mg/d i.v. (d1-3)
    • Etoposide 100 mg/m²/d i.v. (d1-3)
    • Ifosfamide 1500 mg/m²/d i.v. (d1-3)
    • Carboplatin 300 mg/m² i.v. (d1)
    Intervention: Drug: Arm A (Fortecortin®-ETOPOPHOS®-IFO-cell®-CARBO-cell®)
  • Active Comparator: Arm B

    Induction Treatment 4 cycles MATRix (every 3 weeks), stem-cell harvest after 2nd cycle:

    • Rituximab 375 mg/m²/d i.v. (d0,5)
    • Methotrexate 3.5 g/m² i.v. (d1)
    • Cytarabine 2 x 2 g/m²/d i.v. (d2-3)
    • Thiotepa 30 mg/m² i.v. (d4)

    Consolidation Treatment High-dose chemotherapy

    • Carmustine* 400 mg/m² i.v. (d-6)
    • Thiotepa 2 x 5 mg/kg/d i.v. (d-5-(-4))
    • Autologous Stem Cell Transplantation (d0)

      *if not available at study site, Busulfan can be administered instead:

    • Busulfan 3,2 mg/kg/d i.v. (d-8-(-7))
    • Thiotepa 2 x 5 mg/kg/d i.v. (d-5-(-4))
    • Autologous Stem Cell Transplantation (d0)
    Intervention: Drug: Arm B (TEPADINA®-CARMUBRIS®-Busilvex®)
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Unknown status
Estimated Enrollment  ICMJE
 (submitted: August 24, 2015)
250
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE December 2019
Estimated Primary Completion Date November 2017   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Immunocompetent patients with newly-diagnosed primary central nervous system B-cell lymphoma
  2. Age 18-65 years irrespective of ECOG or 66-70 years (with ECOG Performance Status ≤2)
  3. Histologically or cytologically assessed diagnosis of B-cell lymphoma by local pathologist.
  4. Diagnostic sample obtained by stereotactic or surgical biopsy, CSF cytology examination or vitrectomy
  5. Disease exclusively located in the CNS
  6. At least one measurable lesion
  7. Previously untreated patients (previous or ongoing steroid treatment admitted)
  8. Sexually active patients of childbearing potential who agree to take adequate contraceptive measures during study participation
  9. Written informed consent obtained according to international guidelines and local laws by patient or authorized legal representative in case patient is temporarily legally not competent due to his or her disease

ADDITIONAL RANDOMIZATION CRITERIA

  1. Sufficient stem cell harvest (≥ 5 x 106 CD34+ cells/kg of body weight)
  2. Complete remission, unconfirmed complete remission or partial remission
  3. Central pathology results confirming local results

Exclusion Criteria:

  1. Congenital or acquired immunodeficiency
  2. Systemic lymphoma manifestation (outside the CNS)
  3. Isolated ocular lymphoma without manifestation in the brain parenchyma or spinal cord
  4. Previous or concurrent malignancies with the exception of surgically cured carcinoma in-situ of the cervix, carcinoma of the skin or other kinds of cancer without evidence of disease for at least 5 years
  5. Previous Non-Hodgkin lymphoma at any time
  6. Inadequate bone marrow (platelet count decreased ≥CTC grade 1, anemia ≥CTC grade 1, neutrophil count decreased ≥CTC grade 1), renal (creatinine clearance <60 ml/min), cardiac (ejection fraction decreased ≥CTC grade 2), or hepatic function (blood bilirubin increased ≥CTC grade 2, alanine aminotransferase increased ≥CTC grade 2, aspartate aminotransferase increased ≥CTC grade 2 or gamma-GT increased ≥CTC grade 2)
  7. HBsAg, anti-HBc or HCV positivity
  8. HIV infection, previous organ transplantation or other clinical evident form of immunodeficiency
  9. Concurrent treatment with other experimental drugs or participation in a clinical trial within the last thirty days before the start of this study
  10. Symptomatic coronary artery disease, cardiac arrhythmias uncontrolled with medication or myocardial infarction within the last 6 months (New York Heart Association Class III or IV heart disease)
  11. Severe non-compensated pulmonary disease (IVC <55%, DLCO <40%)
  12. Third space fluid accumulation >500 ml
  13. Hypersensitivity to study treatment or any component of the formulation
  14. Taking any medications likely to cause interactions with the study medication
  15. Known or persistent abuse of medication, drugs or alcohol
  16. Patient without legal capacity and who is unable to understand the nature, significance and consequences of the study and without designated legal representative
  17. Persons who are in a relationship of dependency/employment to the sponsor and/ or investigator
  18. Any familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
  19. Concurrent (or planned) pregnancy or lactation
  20. Fertile patients refusing to use safe contraceptive methods during the study
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 70 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Germany
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02531841
Other Study ID Numbers  ICMJE DRKS00005503
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Elisabeth Schorb, University Hospital Freiburg
Study Sponsor  ICMJE University Hospital Freiburg
Collaborators  ICMJE
  • German Federal Ministry of Education and Research
  • International Extranodal Lymphoma Study Group (IELSG)
Investigators  ICMJE
Principal Investigator: Gerald Illerhaus, PhD Representative of Sponsor
PRS Account University Hospital Freiburg
Verification Date August 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP